Comparing the current results to its competitors, Ernexa Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 2.7 %, recorded in the same quarter.
Ernexa Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in the development of treatments for solid tumors and autoimmune diseases, with a focus on mesenchymal stem cell (MSC)-based therapies. Competitors in the MSC therapy space include Mesoblast, an Australia-based regenerative medicine company that has launched RYONCIL® for steroid-refractory acute graft-versus-host disease, as well as U.S.-based companies such as BrainStorm Cell Therapeutics, RESTEM, Celltex, Baylx, Calidi Bio, Akan Biosciences, and ImStem. In the area of platinum-resistant ovarian cancer, competing therapies include Avastin® by Genentech (Roche Group) and ELAHERE® by ImmunoGen. Additional pharmaceutical and biotechnology companies with late-stage or clinical-stage candidates in this field include Corcept Therapeutics, Daiichi Sankyo, Genmab, Merck & Co., and Genelux Corporation. These competitors often possess greater resources and strategic partnerships, which may influence market acceptance and the development of the company's products.
Palatin Technologies Inc has a business model focused on developing and commercializing innovative medicines in the field of reproductive healthcare and sexual dysfunction. The company's revenue streams primarily come from partnerships, licensing agreements, and product sales.
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Pepgen Inc is a biotechnology company that operates on a business model focused on developing and commercializing transformative therapies for genetic diseases. They leverage their expertise in synthetic biology and gene editing technologies to create novel peptide-based therapies that can address previously untreatable genetic conditions. Pepgen Inc aims to partner with healthcare organizations and pharmaceutical companies to bring their innovative treatments to market.
Opko Health Inc is a biotechnology and pharmaceutical company that operates through various business segments. The company primarily focuses on diagnostics, developing and commercializing novel diagnostic tests for various conditions. Additionally, Opko Health engages in the production and sale of pharmaceuticals and vaccines, as well as the research and development of new medical technologies.
Novavax Inc is a biotechnology company focused on the discovery, development, and commercialization of novel vaccines. They aim to leverage their proprietary recombinant nanoparticle vaccine technology platform to address a wide range of infectious diseases. By collaborating with partners and conducting clinical trials, Novavax works towards bringing innovative vaccines to the global market.
Sources:
Ernexa Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Ernexa Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
